Table 4

Application of original MSS1, current MSS2 and new pathology-adjusted Manchester score MSS3 to 4113 index cases from unrelated families affected by breast/ovarian cancer

Manchester score	<15			15–19			20–24			25–29			30+			Total mutation	Total tested	%	BRCA1	%	BRCA2	%
	BRCA1/2	Number tested	%	BRCA1/2	Number tested	%	BRCA1/2	Number tested	%	BRCA1/2	Number tested	%	BRCA1/2	Number tested	%
ER− HER2+ original MSS1	0	19	0.0	0	10	0.0	2	10	20.0	2	6	33.3	2	3	66.7	6	48	12.5	4	8.3	2	4.2
ER− HER2+ current MSS2	0	28	0.0	2	9	22.2	1	6	16.7	2	4	50.0	1	1	100.0	6	48	12.5	4	8.3	2	4.2
ER− HER2+ new MSS3	0	26	0.0	2	11	18.2	1	6	16.7	2	4	50.0	1	1	100.0	6	48	12.5	4	8.3	2	4.2
ER+ HER2+ MSS1	1	48	2.1	1	28	3.6	3	28	10.7	1	17	5.9	0	9	0.0	6	130	4.6	1	0.8	5	3.8
ER+ HER2+ MSS2	2	72	2.8	3	32	9.4	1	16	6.3	0	5	0.0	0	5	0.0	6	130	4.6	1	0.8	5	3.8
ER+ HER2+ MSS3	2	80	2.5	3	28	10.7	1	13	7.7	0	8	0.0	0	1	0.0	6	130	4.6	1	0.8	5	3.8
TNT MSS1	32	250	12.8	33	89	37.1	30	66	45.5	23	31	74.2	41	47	87.2	159	483	32.9	125	25.9	34	7.0
TNT MSS2	11	137	8.0	24	119	20.2	37	101	36.6	30	57	52.6	57	69	82.6	159	483	32.9	125	25.9	34	7.0
TNT MSS3	7	112	6.3	13	86	15.1	39	126	31.0	29	69	42.0	71	90	78.9	159	483	32.9	125	25.9	34	7.0
TNT<30	0	0	0.0	4	24	16.7	2	4	50.0	3	8	37.5	13	14	92.9	22	50	44.0	19	38.0	3	6.0
TNT 30–39	3	75	4.0	3	20	15.0	14	46	30.4	10	20	50.0	30	38	78.9	60	199	30.2	53	26.6	7	3.5
TNT 40–49	3	28	10.7	5	27	18.5	15	39	38.5	9	23	39.1	22	27	81.5	54	144	37.5	40	27.8	14	9.7
TNT 50+	1	9	11.1	2	15	13.3	8	36	22.2	6	19	31.6	6	11	54.5	23	90	25.6	13	14.4	10	11.1
HGSOC MSS2+	15	140	10.7	7	43	16.3	10	24	41.7	3	8	37.5	3	5	60.0	38	220	17.3	29	13.2	9	4.1
HGSOC MSS3+	0	24	0.0	20	155	12.9	5	20	25.0	10	17	58.8	3	4	75.0	38	220	17.3	29	13.2	9	4.1
All ovarian case MSS3	3	96	3	30	255	11.8	31	114	27.2	39	110	35.5	87	139	62.6	190	714	26.6	123	17.2	67	9.4
All ovarian MSS1*	18	206	8.7	34	253	13.4	65	266	24.4	66	234	28.2	182	308	59.1	365	1267	28.8	227	17.9	138	10.9
Ovarian MSS2*	18	248	7.3	23	244	9.4	69	266	25.9	68	205	33.2	187	304	61.5	365	1267	28.8	227	17.9	138	10.9
All ovarian* MSS3	3	134	2.2	37	349	10.6	56	247	22.7	78	224	34.8	191	313	61.0	365	1267	28.8	227	17.9	138	10.9
Ovarian path adjusted only confirmed ovarian cancer	9	214	4.2	38	357	10.6	66	237	27.8	83	209	39.7	169	250	67.6	365	1267	28.8	227	17.9	138	10.9
Breast-only MSS1	65	1372	4.7	74	700	10.4	89	441	20.2	55	185	29.7	70	151	46.4	352	2849	12.4	157	5.5	195	6.8
Breast-only MSS2	49	1316	3.7	74	789	9.4	89	396	22.5	58	191	30.4	83	157	52.9	353	2849	12.4	157	5.5	195	6.8
Breast-only MSS3	43	1292	3.3	66	757	8.7	95	434	21.9	56	194	28.9	93	172	54.1	353	2849	12.4	157	5.5	195	6.8
Breast MSS3 with path avail	33	920	3.6	63	625	10.1	103	411	25.1	84	243	34.6	180	287	62.7	463	2486	18.6	131	5.3	144	5.8
Breast/ovarian path avail MSS1	73	1165	6.3	92	709	13.0	126	525	24.0	103	325	31.7	207	361	57.3	601	3085	19.5	335	10.9	266	8.6
Breast/ovarian path avail MSS2	56	1130	5.0	82	789	10.4	128	486	26.3	109	312	34.9	226	368	61.4	601	3085	19.5	335	10.9	266	8.6
Breast/ovarian path avail MSS3	35	995	3.5	88	859	10.2	124	509	24.4	114	330	34.5	240	392	61.2	601	3085	19.5	335	10.9	266	8.6

*All ovarian cases and those with ovarian cancer family history. Only cases with proven high grade were included where no further ovarian cancers were present in the family. +HGSOC, high-grade serous ovarian cancer; path avail, pathology available; TNT, triple-negative tumour.